Cushing’s syndrome (CS) describes the signs and symptoms that are secondary to persistent hypercortisolemia, including stigmata of hypertension, diabetes, truncal obesity, osteopenia, bruising, abdominal striae, moon facies, generalized malaise, fatigue, and emotional lability. Cushing’s disease (CD) is restricted to hypercortisolemia secondary to an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma. CD accounts for approximately 70% of adult cases of CS [1]. The prompt identification and treatment of CD is paramount since CD left untreated can carry a high morbidity and mortality. Untreated CD has a 5-year survival rate of only 50% [2].